The effects of cardiac drugs on human erythrocyte carbonic anhydrase I and II isozymes
Cardiovascular diseases are the leading cause of mortality worldwide. In recent years, the relationship between carbonic anhydrase inhibitors and atherosclerosis has attracted attention. In this study, we aimed to determine the in vitro effects of 35 frequently used cardiac drugs on human carbonic anhydrase I (hCA I) and II (hCA II). The inhibitory effects of the drugs on hCA I and hCA II were determined with both the hydratase and esterase methods. The most potent inhibitors observed were propafenone (hCA I: 2.8 µM and hCA II: 3.02 µM) and captopril (hCA I: 1.58 µM and hCA II: 6.25 µM). Isosorbide mononitrate, propranolol, furosemide, and atorvastatin were also potent inhibitors. The inhibitor constant, Ki, value from the Lineweaver-Burk plot for propafenone was 2.38 µM for hCA I and 2.97 µM for hCA II. The tested cardiac drugs showed potent in vitro inhibition of the hCA I and II isozymes. Especially, in patients with atherosclerotic heart disease, these drugs may be preferred primarily due to the beneficial effects of carbonic anhydrase inhibition on atherosclerosis.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:35 |
|---|---|
| Enthalten in: |
Journal of enzyme inhibition and medicinal chemistry - 35(2020), 1 vom: 16. Dez., Seite 1359-1362 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Argan, Onur [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Acetazolamide |
|---|
| Anmerkungen: |
Date Completed 19.02.2021 Date Revised 30.03.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1080/14756366.2020.1781844 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM311460070 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM311460070 | ||
| 003 | DE-627 | ||
| 005 | 20240330232553.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/14756366.2020.1781844 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1356.xml |
| 035 | |a (DE-627)NLM311460070 | ||
| 035 | |a (NLM)32567385 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Argan, Onur |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The effects of cardiac drugs on human erythrocyte carbonic anhydrase I and II isozymes |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.02.2021 | ||
| 500 | |a Date Revised 30.03.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Cardiovascular diseases are the leading cause of mortality worldwide. In recent years, the relationship between carbonic anhydrase inhibitors and atherosclerosis has attracted attention. In this study, we aimed to determine the in vitro effects of 35 frequently used cardiac drugs on human carbonic anhydrase I (hCA I) and II (hCA II). The inhibitory effects of the drugs on hCA I and hCA II were determined with both the hydratase and esterase methods. The most potent inhibitors observed were propafenone (hCA I: 2.8 µM and hCA II: 3.02 µM) and captopril (hCA I: 1.58 µM and hCA II: 6.25 µM). Isosorbide mononitrate, propranolol, furosemide, and atorvastatin were also potent inhibitors. The inhibitor constant, Ki, value from the Lineweaver-Burk plot for propafenone was 2.38 µM for hCA I and 2.97 µM for hCA II. The tested cardiac drugs showed potent in vitro inhibition of the hCA I and II isozymes. Especially, in patients with atherosclerotic heart disease, these drugs may be preferred primarily due to the beneficial effects of carbonic anhydrase inhibition on atherosclerosis | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Cardiac drugs | |
| 650 | 4 | |a carbonic anhydrase | |
| 650 | 4 | |a enzyme inhibition | |
| 650 | 7 | |a Carbonic Anhydrase Inhibitors |2 NLM | |
| 650 | 7 | |a Carbonic Anhydrase I |2 NLM | |
| 650 | 7 | |a EC 4.2.1.- |2 NLM | |
| 650 | 7 | |a Carbonic Anhydrase II |2 NLM | |
| 650 | 7 | |a EC 4.2.1.- |2 NLM | |
| 650 | 7 | |a Acetazolamide |2 NLM | |
| 650 | 7 | |a O3FX965V0I |2 NLM | |
| 700 | 1 | |a Çıkrıkçı, Kübra |e verfasserin |4 aut | |
| 700 | 1 | |a Baltacı, Aybike |e verfasserin |4 aut | |
| 700 | 1 | |a Gencer, Nahit |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of enzyme inhibition and medicinal chemistry |d 2002 |g 35(2020), 1 vom: 16. Dez., Seite 1359-1362 |w (DE-627)NLM121560376 |x 1475-6374 |7 nnns |
| 773 | 1 | 8 | |g volume:35 |g year:2020 |g number:1 |g day:16 |g month:12 |g pages:1359-1362 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/14756366.2020.1781844 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 35 |j 2020 |e 1 |b 16 |c 12 |h 1359-1362 | ||